(Reuters) -Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the blockbuster treatment. J&J over the past two years has signed settlement agreements with several companies to delay the US launches of Stelara, which has been its top-selling drug since 2019. The first biosimilar, Amgen's Wezlana, was launched in January this year. Biocon Biologics is set to launch its version of the drug sometime this month, while Fresenius Kabi is expected to follow with its own launch in April. UBS analyst Ashwani Verma said the launch of Selarsdi "can establish the success path and playbook for more biosimilars to come."